Last reviewed · How we verify
NCT06975813
Magnesium Sulfate and Trigger Points
Phase 2 trial testing masseter muscle in Myofascial Pain Syndrome in 30 participants. Not yet recruiting.
30 December 2025
Quick facts
| Lead sponsor | Fayoum University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 June 2025 |
| Primary completion | 30 December 2025 |
| Estimated completion | 27 January 2026 |
Drugs / interventions tested
- masseter muscle — full drug profile →
- masseter and sternocleidomastoid muscle — full drug profile →
Conditions studied
- Myofascial Pain Syndrome — all drugs for Myofascial Pain Syndrome →
Sponsor
Fayoum University
Who can join
18 and older, any sex, with Myofascial Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The patients will be randomly assigned to one of the two groups according to the treatment method: group I (masseter group) and group II (masseter \&sternocleidomastoid group) where each patient will be injected 0.5ml in each trigger point (TrPs) of magnesium sulphate according to the treatment group by the same operator. The treatment method for TrPs will be the primary predictor variable. Patients will be examined at the following intervals: during diagnosis, 1-month, 3-months, and 6-months post-injection. The participated patients will be assessed using pain score measured on a 10-point visual analogue scale (VAS), the 0 indicating no pain and 10 indicating the worst pain ever
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06975813
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myofascial Pain Syndrome
Currently open trials in the same condition.
- NCT07511751 — COMPARISON OF THREE TREATMENT MODALITIES İN MYOFASCIAL PAIN SYNDROME · NA · recruiting
- NCT07045324 — Effect of Vagus Nerve Stimulation on Trapezius Trigger Point · NA · active not recruiting
Other Fayoum University trials
Trials by the same sponsor.
- NCT07536620 — Metformin and Alveolar Cleft · Phase 2 · not yet recruiting
- NCT07444970 — Comparative Evaluation of Xenograft Alone and Sticky Bone in Sinus Lift With Concurrent Implant Placement · NA · not yet recruiting
- NCT07394179 — Transforming Channel Osteotomy Into Tunnel Osteotomy in Zygomatic Implant Preparation · NA · not yet recruiting
- NCT07277348 — Analysis of The Outcomes of Therapeutic Photorefractive Keratectomy Combined With Prophylactic Accelerated Cross-Linking · NA · not yet recruiting
- NCT07330726 — Lidocaine Patch and Lower Third Molar · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06975813 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fayoum University
- Last refreshed: 16 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06975813.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing